Ixabepilone - CAS 219989-84-1
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Ixabepilone (also known as azaepothilone B, or BMS-247550) is an orally bioavailable microtubule inhibitor. Ixabepilone was a semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Ixabepilone was approved in 2007.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-063099 5 mg $198 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Azaepothilone B; BMS 247550; BMS 247550-1; Ixempra
1.Mechanism of action of ixabepilone and its interactions with the βIII‑tubulin isotype
Manu Lopus • Greg Smiyun • Herb Miller • Emin Oroudjev • Leslie Wilson • Mary Ann Jordan. Cancer Chemother Pharmacol (2015) 76:1013–1024
Here we examined ixabepilone’s binding to microtubules and its effects on microtubule assembly in vitro and on the parameters of microtubule dynamic instability both in vitro with microtubules assembled from puriied tubulin and with microtubules in MCF7 breast cancer cells. We found that ixabepilone binds to microtubules with a variable stoichiometry of 1–2 molecules of drug for every tubulin molecule in microtubules. The absence or reduction of βIII-tubulin makes microtubules more susceptible to the suppressive effects of ixabepilone on dynamic instability in vitro and in cells and enhances mitotic arrest. Our results indicate that βIII-tubulin reduces the effects of ixabepilone on microtubule dynamics and on mitotic arrest, and thus increased βIII-tubulin expression may contribute to ixabepilone resistance in tumors.
2.Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Neelima Denduluri • James J. Lee • Janice Walshe • Arlene W. Berman • Ujala Vatas • Catherine K. Chow. Invest New Drugs (2006) 25:63–67
Finally, this trial was designed to rule out a 5% response rate in favor of a 20%response rate using a two stage design. With only 12 patients enrolled and no responses, there is a 90% chance that the true response rate is 17.5% or less. Given the number of other positive trials with this agent, it is possible that the current trial has produced a false negative result, although it is unlikely that the true response ratewould be 20% or higher. Unlike previous trials with efficacy of ixabepilone in breast cancer with different dosing schedules, our trial suggests that the 8–10 mg/m2 daily for 3 days regimen may not be an effective therapy in this heavily pretreated population. Current Phase III trials with ixabepilone should give us more definitive conclusions about the therapeutic efficacy of different dose schedules of ixabepilone in metastatic breast cancer.
3.Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients
Ellen B. Kossoff • Nuttapong Ngamphaiboon • Thomas J. Laudico • Tracey L. O’Connor. Med Oncol (2011) 28:S115–S120
Weekly paclitaxel is regarded as a standard of care in metastatic breast cancer due to improvements in efficacy and tolerability seen with this schedule. The Cancer and Leukemia Group B (CALGB 9840) demonstrated that weekly paclitaxel was superior to every 3-week paclitaxel as treatment of metastatic breast cancer with improvements seen in RR (42%vs. 29%) and TTP (median, 9 vs. 5 months) with this schedule. Because ixabepilone is pharmacologically similar to the taxanes, weekly administration of ixabepilone may offer similar benefits to those of weekly paclitaxel. The available clinical data,while limited, suggest that weekly ixabepilone is a reasonable option for breast cancer patients.
4.Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment
Chao-Chiang Tu & Chien-Yu Huang & Wan-Li Cheng & Chin-Sheng Hung. Tumor Biol.
Taxanes are potent antimicrotubule agents that are used in the treatment of advanced gastric cancer as first- and second-line therapies and that have response rates of approximately 15∼24%. However, the majority of patients with advanced gastric cancer eventually develop progressive diseases after initially responding to taxane-based treatment. Ixabepilone, a semisynthetic analog of epothilone B, promotes tumor cell death by stabilizing microtubules and inducing apoptosis similar to taxanes. In fact, ixabepilone structurally differs from taxanes and is less susceptible to tumor resistance mechanisms, including P-glycoprotein overexpression and beta-tubulin mutations, the two most common mechanisms of resistance to paclitaxel. In addition, ixabepilone is more potent than paclitaxel in promoting beta-tubulin polymerization in both paclitaxel-sensitive and paclitaxel-resistant cell lines. Accumulating clinical trials have proven the efficacy of ixabepilone in a broad variety of tumor types, including metastatic or treatment-resistant breast cancer, advanced prostate cancer, pancreatic cancer, non-small cell lung cancer, endometrial carcinoma, ovarian cancer, and renal cell carcinoma. The US Food and Drug Administration has approved ixabepilone for the treatment of locally advanced breast cancer since 2007. Trials examining ixabepilone as a monotherapy or in combination with other classical cytotoxics are currently in progress, and further roles for ixabepilone in the treatment of cancer are hoped for
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products

CAS 194468-36-5 Vinflunine ditartrate

Vinflunine ditartrate
(CAS: 194468-36-5)

Vinflunine, a semisynthetic derivative of Vinorelbine, is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family endowed with uniqu...

CAS 518-28-5 Podophyllotoxin

(CAS: 518-28-5)

Podophyllotoxin, a kind of non-alkaloid toxin lignan extracted from the roots and rhizomes of Podophyllum plant, has been shown to inhibit the growth of various...

CAS 148408-66-6 Docetaxel Trihydrate

Docetaxel Trihydrate
(CAS: 148408-66-6)

Docetaxel is a cytotoxic agent, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by...

CAS 74588-78-6 D-64131

(CAS: 74588-78-6)

D-64131, under the IUPAC name (5-methoxy-1H-indol-2-yl)-phenylmethanone, is a 2-aroylindole derivatives that inhibits tubulin polymerization. In vitro: Inhibits...

CAS 474645-27-7 MMAE

(CAS: 474645-27-7)

MMAE, whose full name is Monomethyl auristatin E, inhibits tubulin polymerization so that it inhibits cell division.

C2N 8E12

C2N 8E12 is a humanized antibody that currently in clinical development works to protect against Alzheimer’s disease by stimulating the immune system to activat...

CAS 152044-54-7 Epothilone B

Epothilone B
(CAS: 152044-54-7)

Epothilone B, also called Patupilone, is a microtubule stabilization agent (EC0.01= 1.8 μM). It induces mitotic arrest at the G2-M transition in Hs578T (IC50 = ...

CAS 6559-91-7 4'-Demethylepipodophyllotoxin

(CAS: 6559-91-7)

4'-Demethylepipodophyllotoxin is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs. It is a potent inhibitor of microtub...

CAS 865-21-4 Vinblastine

(CAS: 865-21-4)

Vinblastine is inhibitor of nAChR and can inhibit the formation of microtubule. It is a natural alkaloid isolated from the plant Vinca rosea Linn. It binds to t...

Flutax 1
(CAS: 191930-58-2)

Flutax 1, the more soluble difluoro-fluorescein derivative with improved photostability Flutax-2, binds to the taxol microtubule binding site with high affinity...

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 441045-17-6 eribulinmesilate

(CAS: 441045-17-6)

Eribulinmesilate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-e...

CAS 442-51-3 Harmine

(CAS: 442-51-3)

Harmine induces apoptosis and inhibits proliferation, migration and invasion of human gastric cancer cells, which may be mediated by down-regulation of COX-2 ex...

CAS 41179-33-3 CMPD-1

(CAS: 41179-33-3)

CMPD-1, also called MK2a Inhibitor, inhibits tubulin polymerisation. It inhibit p38α-mediated MK2a phosphorylation (apparent Ki = 330 nM).

CAS 114977-28-5 Docetaxel

(CAS: 114977-28-5)

Docetaxel, also called Taxoltere metro, a semisynthetic side-chain analogue of taxol differing at two positions in its chemical structure, is an inhibitior of m...

CAS 917369-31-4 MPC 6827 hydrochloride

MPC 6827 hydrochloride
(CAS: 917369-31-4)

MPC 6827 hydrochloride, the hydrochloride salt form of verubulin, inhibits of microtubule formation (IC50 = 1.5 - 3.4 nM). in vitro: inhibits polymerization of...


AADvac-1 is an active vaccine designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These ...

CAS 729605-21-4 XRP44X

(CAS: 729605-21-4)

XRP44X, under the IUPAC name [4-(3-chlorophenyl)piperazin-1-yl]-(5-methyl-2-phenylpyrazol-3-yl)methanone, as an inhibitor of Tubulin it indirectly inhibits Net ...

CAS 1233948-35-0 ELR510444

(CAS: 1233948-35-0)

ELR510444 is a potent microtube disruptor with potential anticancer activity. ELR510444 has potent microtubule-disrupting activity, causing a loss of cellular m...

CAS 14255-87-9 Parbendazole

(CAS: 14255-87-9)

Parbendazole, a benzimidazole carbamat used as an antinematodal agent, is a potent inhibitor of microtubule assembly and functions.

Chemical Structure

CAS 219989-84-1 Ixabepilone

Quick Inquiry

Verification code

Featured Items